Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$1.53 USD
-0.06 (-3.77%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.58 +0.05 (3.27%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SNSE 1.53 -0.06(-3.77%)
Will SNSE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SNSE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SNSE
Buy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial Stability
Sensei Biotherapeutics initiated with bullish view at Stephens, here's why
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
Sensei Biotherapeutics Poised for Growth: A Strong Buy Rating Amid Financial Stability and Promising Clinical Trials
SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024